The information provided in this section is intended expressly for healthcare professionals in the United States. Click “OK” to enter if you are a US healthcare professional.
STIVARGA® (regorafenib) is an oral inhibitor of multiple kinases
Target normal cellular functions and pathological processes such as oncogenesis, tumor angiogenesis, metastasis, and tumor immunity1, 2
In invitro biochemical or cellular assays, STIVARGA or its major human active metabolites, M-2 and M-5, inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, Abl, and CSF1R at concentrations of STIVARGA that have been achieved clinically1
In invivo models, STIVARGA demonstrated anti-angiogenic activity in a rat tumor model and inhibition of tumor growth in several mouse xenograft models including some for human colorectal carcinoma. STIVARGA also demonstrated anti-metastatic activity in a mouse xenograft model and 2 mouse orthotopic models of human colorectal carcinoma1
View aspects of mCRC mechanism of disease at the cellular level
This video explores key aspects of tumor function and pathologic processes in the mCRC tumor microenvironment.